Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject satisfied Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for a primary diagnosis of Bipolar Disorder, most recently manic~* The patient is willing to be hospitalized on an inpatient psychiatric unit for a minimum of seven (7) days.~* Subject has been treated with lithium in the past.~* Subject has been treated with divalproex or carbamazepine in the past.~* Subject has been treated with Haldol or haloperidol in the past.~Exclusion Criteria:~* Subjects lacks the capacity to provide informed consent~* Subject is a serious suicide risk or has medically unstable conditions as judged by the investigators~* Subject has been dependent on a drug (other than nicotine or caffeine) in the last three (3) months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: EXPERIMENTAL): Subjects were be started on a standardized minimum first-day dose of 15 mg olanzapine. After the first day of therapy, the daily dose was either increased or decreased, as clinically indicated, by 5 mg, within an allowed range of 5 to 40 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).